Company intelligence / Profile preview

KronosMD

San Mateo, California, United States

Ownership: Private
Development stage: Other

Overview

Kronos Bio’s current lead asset, istisociclib (CDK9 inhibitor), is in Phase 1/2 for MYC-dependent tumors. KB-9558 (p300 KAT inhibitor) and KB-7898 (another p300 inhibitor for autoimmune indication) are in preclinical/early development. Some previous AML assets (entospletinib) have been discontinued in late-stage trials[3][4].

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeCDK9 inhibitorp300 KAT inhibitor
Industry: Biotech

Beyond the preview

Go deeper on KronosMD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KronosMD.

Explore the full profile